Jia (Jenny) Liu, Translational Lead, Early Phase Drug Development at The Kinghorn Cancer Centre, shared a post on X about a paper she co-authored with colleagues published in Nature Medicine:
“Insightful presentation by Paolo Tarantino at ESMO25 on ADC toxicity strategies in drug development.
We need to take learnings from decades of cytotoxic chemotherapy to ensure that ADCs are safe and tolerable. Our IBI343 CLDN18.2 ADC e.g., Fc silenced ADC.”
Title: CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial
Authors: Jia Liu, Jianwei Yang, Yuping Sun, Jifang Gong, Jinbo Yue, Yueyin Pan, Meili Sun, Rongfeng Song, Xiuying Xiao, Andrea Tazbirkova, Jian Ruan, Zhenyang Liu, Zimin Liu, Zhihua Li, Lili Sheng, Yanru Qin, Jieer Ying, Xianjun Yu, Jian Zhang, Yiping Mou, Chuangxin Lu, Ping Chen, Suyi Li, Jie Li, Xiujuan Qu, Ting Deng, Juan Du, Aiping Zhou, Enxiao Li, Xianglin Yuan, Xinjun Liang, Weiming Yu, Michelle Morris, Yang Luo, Xin Zhao, Yingmei Guo, Hui Zhou, Lin Shen
You can read the Full Article in Nature Medicine.
Follow the latest ESMO 2025 news on OncoDaily.
